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Abstract
Objective: To demonstrate that the administration of an angiotensin (Ang) II type 1 receptor (AT1R) blocker (ARB) inhibits the 
vicious cycle of high glucose (HG)-reactive oxygen species (ROS)-angiotensinogen (AGT)-Ang II-AT1R-ROS by suppressing 
ROSs and inflammation, thus ameliorating diabetic nephropathy (DN).
Research Design and Methods: Thirteen hypertensive DN patients were administered ARBs, and the following parameters were 
evaluated before and 16 weeks after the treatment: urinary AGT (UAGT), albumin (albumin-creatinine ratio: ACR), 8-hydroxyde-
oxyguanosine (8-OHdG), 8-epi-prostaglandin F2α (8-epi-PGF2α), monocyte chemoattractant protein (MCP)-1, interleukin (IL)-6, 
and IL-10.
Results: ARB treatment reduced the blood pressure and urinary levels of AGT, ACR, 8-OHdG, 8-epi-PGF2α, MCP-1, and IL-6 but 
increased the urinary levels of IL-10. The reduction rate of UAGT correlated with the reduction rate of blood pressure; the reduction 
rates of the urinary ACR, 8-OHdG, 8-epi-PGF2α, MCP-1, and IL-6 levels; and the increase rate of the urinary IL-10 levels. Moreover, 
subjects who had high UAGT values at baseline exhibited higher reduction rates of urinary albumin excretion.
Conclusions: ARB-induced blockade of the abovementioned vicious cycle contributes to the renoprotective effects of ARBs in DN. The 
urinary levels of AGT could represent a predictive factor for reduced ACR in patients receiving ARB treatment.
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Introduction
High glucose (HG) levels lead to increased angiotensin 
(Ang) II generation in the kidney. Reactive oxygen 
species (ROSs) mediate a process that increases the 
levels of angiotensinogen (AGT), leading to increased 
Ang II generation.1–3 HG induces AGT generation 
via  the  ROS–AGT  pathway.4–6  AGT  generation 
mediated  by  HG-induced  ROSs,  accompanied  by 
increased local production of Ang II, causes many 
pathophysiological changes associated with diabetic 
nephropathy (DN).7–9 Ang II induces a further increase 
in the intracellular ROS levels via the activation of 
the Ang  II  type  1  receptor  (AT1R).10–11  Increased 
ROS  levels,  whatever  they  may  be  attributed  to, 
cause  inflammation  and  renal  damage.  Monocyte 
chemoattractant  protein  (MCP)-1  and  interleukin 
(IL)-6 are assumed to be the key inflammatory factors 
involved in these effects. The renoprotective action 
of an AT1R blocker (ARB) is strongly related to its 
ROS-lowering  effects.10  In  DN,  the  generation  of 
ROS, AGT, and Ang II seems to increase remarkably 
when  the  vicious  cycle  of  HG-ROS-AGT-Ang 
II-AT1R-ROS is activated.1–9
An ARB is expected to block this vicious cycle 
and thus decrease the urinary levels of inflammatory 
markers, ROS markers, albumin (measured as the albumin-
creatinine ratio [ACR]), and AGT. Furthermore, all 
such effects of an ARB are expected to be closely 
correlated.  However,  these  effects  have  not  yet 
been clinically investigated. The present study was 
designed to confirm that AT1R blockade reduces the 
urinary AGT (UAGT) levels and to determine whether 
changes in these levels are closely related to changes 
in the ACR and in the levels of urinary ROSs and 
inflammatory markers. We therefore determined the 
ACR and the levels of UAGT, inflammatory markers, 
and ROSs before and after the administration of ARB 
to DN patients.
Research Design and Methods
The  subjects  enrolled  in  the  present  study  were 
outpatients  with  hypertensive  type  2  DN  at  our 
hospital.  The  enrollment  criteria  were  as  follows: 
mild  to  moderate  hypertension  (office  systolic 
blood  pressure  (SBP)  =  130–199  and/or  diastolic 
blood pressure (DBP) = 70–110 mmHg), no use of 
antihypertensive agents such as RAS inhibitors, HbA1c 
levels  8%, ACR  30 µg/mg Cre, and absence 
of  hematuria.  The  present  study  was  conducted 
after  we  obtained  informed  consent  from  all  the 
subjects, and the study protocol was approved by the 
ethics  committees  of  Tohoku  University  Hospital. 
Although 20 patients were initially enrolled, 7 were 
subsequently  excluded  for  various  reasons.  Thus, 
the  study  finally  involved  13  patients  (7  men  and 
6 women) who had had diabetes for 13.4 ± 3.7 years. 
The subjects were administered ARBs (olmesartan 
in the case of 7 patients and valsartan in the case 
of  6).  The  following  parameters  were  measured 
before  and  16  weeks  after  the  treatment:  UAGT; 
oxidative stress markers such as 8-epi-prostaglandin 
F2α  (8-epi-PGF2α)  and  8-hydroxydeoxyguanosine 
(OHdG);  the  inflammatory  markers  MCP-1,  IL-6, 
and IL-10; and the ACR.10 The UAGT levels were 
determined using a newly developed ELISA.12–14 The 
ACR and the levels of UAGT, 8-epi-PGF2α, 8-OHdG, 
MCP-1, IL-6, and IL-10 were expressed in terms of 
the  median  (range),  because  these  factors  did  not 
exhibit normal distribution. The difference between 
the values determined before and after the treatment 
was analyzed using the Wilcoxon signed-rank test. All 
the other data were expressed as the mean ± standard 
error  of  the  mean  (SEM)  and  were  statistically 
analyzed using the paired Student t test. Correlations 
were determined using the Spearman rank correlation 
test. p  0.05 was considered significant.
Results
The changes in the clinical parameters evaluated before 
and after ARB administration were as follows: body 
mass index (kg/m2), from 22.4 ± 0.7 to 22.5 ± 0.6 (not 
significant, p = 0.8994); HbA1c (%), from 6.6 ± 0.3 to 
6.6 ± 0.2 (not significant, p = 0.9804); SBP (mmHg), 
from  161.6  ±  2.8  to  145.7  ±  3.1  (-9.7%  ±  2.2%, 
p  0.01); DBP (mmHg), from 80.8 ± 1.8 to 78.6 ± 1.9 
(-2.2% ± 2.3%, p  0.01); serum creatinine (mg/dl), 
from 1.1 ± 0.1 to 1.3 ± 0.1 (p  0.05); and K+ (mEq/l), 
from 5.0 ± 0.2 to 5.3 ± 0.2 (p  0.05). The ACR and 
the  urinary  levels  of AGT,  8-epi-PGF2α,  8-OHdG, 
MCP-1, and IL-6 were significantly reduced (Table 1). 
However, the plasma levels of these markers remained 
unchanged  (data  not  shown).  The  percent  changes 
in  the  parameters  evaluated  before  and  after  ARB 
administration are shown in Table 1. The reduction rate 
of the UAGT levels correlated with the reduction rates 
of the ACR (y = 0.963x –10.948, r = 0.7290, p  0.001; Angiotensinogen in nephropathy
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Fig. 1A) and the SBP (y = 0.3103x –4.8051, r = 0.8460, 
p  0.001, Fig. 1B); the reduction rates of the 8-OHdG 
(y = 0.9488x –6.9257, r = 0.6551, p  0.01; Fig. 1C), 
8-epi-PGF2α  (y  =  0.6584x  –0.1335,  r  =  0.3561, 
p  0.01; Fig. 1D), MCP-1 (y = 1.1568x –7.2415, 
r = 0.7143, p  0.001; Fig. 2A), and IL-6 (y = 2.4049x 
+0.593, r = 0.6409, p  0.001; Fig. 2B) levels; and the 
increase rate of the IL-10 levels (y = -1.0622x + 33.434, 
r = –0.3299, p  0.01; Fig. 2-C). Subjects who had 
high UAGT levels at baseline exhibited a high ACR 
reduction rate (y = -1.0876x –10.147, r = -0.3599, 
p  0.05; Fig. 3).
Table 1. Urinary parameters evaluated before and 16 weeks after the administration of ArBs.
Parameters Unit Before After p % change
AGT mg/g Cre 12.0 (3.7–39.9) 8.9 (2.5–29.8) 0.05 -15.6 ± 5.8
albumin mg/g Cre 2026 (894–3428) 1232 (548–3783) 0.01 -25.9 ± 7.7
8-epi-pGF2α ng/g Cre 247 (124–802) 207 (113–454) 0.05 -10.4 ± 10.7
8-ohdG µg/g Cre 8.7 (4.3–17.5) 5.4 (4.4–14.8) 0.01 -21.7 ± 8.4
MCp-1 ng/g Cre 575 (51–2170) 652 (37–2620) 0.05 -25.4 ± 9.4
IL-6 ng/g Cre 9.7 (0.2–36.5) 0.8 (0.2–38.5) 0.01 -36.3 ± 21.8
IL-10 ng/g Cre 0.8 (0.3–2.8) 0.9 (0.3–6.3) 0.01 50.0 ± 18.7
notes: The parameters are expressed in term of the median (range). The percent change in the values determined after ArB administration as compared 
to those before administration is expressed as the mean ± SeM.
Abbreviations: AGT, angiotensinogen; 8-epi-pGF2α, 8-epi-prostaglandin F2α; 8-ohdG, 8-hydroxydeoxyguanosine; MCp, monocyte chemoattractant 
protein; Cre, urinary creatinine; IL, interleukin.
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Figure 1. Correlation between the reduction rate of the urinary angiotensinogen (UAGT) levels and that of urinary albumin excretion (ACr): A) reduction 
rate  of  systolic  blood  pressure  (SBp):  B)  reduction  rates  of  the  urinary  8-hydroxydeoxyguanosine  (8-ohdG)  and  urinary  8-epi-prostaglandin  F2α   
(8-epi-pGF2α) levels.ogawa et al
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conclusions
The  results  of  the  present  study  revealed  that  a 
vicious cycle of HG-ROS-AGT-Ang II-AT1R-ROS 
may  operate  in  DN.  The  continuous  increase  in 
the  ROS  levels  contributes  to  the  progression  of 
DN.  ARB  treatment  is  believed  to  suppress  ROS 
production  by  blocking  the  Ang  II-AT1R-ROS 
pathway, thus reducing inflammation and suppressing 
AGT generation.1–11
We previously reported that a reduction in the 
urinary ROS levels is important for ARBs to exert 
their  ACR-lowering  effects,  and  that  even  with 
an  equal  reduction  in  the  blood  pressure;  ARBs 
reduce the ROS levels more effectively than other 
antihypertensive  agents.10  Thus,  the  action  of 
ARBs in reducing the ROS levels is independent 
of a decrease in the blood pressure. Accordingly, 
it seems that the ROS reduction observed in this 
study may be attributed to the blockade of the Ang 
II-ROS  pathway  rather  than  to  decrease  in  blood 
pressure.  The  findings  of  this  study  reveal  that 
changes in the UAGT levels largely influence the 
ARB-induced changes in the ROS levels and ACR. 
The  UAGT  levels  are  reported  to  be  elevated  in 
hypertensive  patients  and  are  correlated  with  the 
ACR;  further, ARB  treatment  reduces  the  UAGT 
levels.12 Changes in the UAGT levels are correlated 
with changes in not only the ACR but also the blood 
pressure; this suggests that AGT in the blood might 
be filtered in the glomeruli and excreted in urine. 
Thus, a reduction in the UAGT levels may merely 
reflect  a  decrease  in  the  intraglomerular  pressure 
rather  than  the  suppression  of  AGT  production. 
However, the ARB-induced reduction in the ACR is 
probably caused by blockade of the ROS-AGT-Ang 
II-AT1R-ROS cycle. This is because 1) the reduction 
in  the  UAGT  levels  correlated  not  only  with  the 
changes in the ACR and blood pressure but also with 
the changes in the levels of ROS and inflammatory 
markers, and 2) AGT is most probably produced in 
renal cells and released in urine.1–8 Another possible 
reason  for  reduced  UAGT  excretion  may  be  that 
ARB  increases  the  renal  tubular  reabsorption  of 
AGT. Unfortunately, we were unable to investigate 
this possibility in the present study.
We  have  previously  reported  that  the  efficacy 
of ARBs  increases  with  urinary  oxidative  stress.10 
Moreover, we confirmed that the greater the UAGT 
excretion, the greater is the ACR suppression induced 
by ARB  administration. The  fact  that  the  subjects 
in  the  present  study  exhibited  increased  UAGT 
and  ROS  levels  indicates  that  the  ROS-AGT-Ang 
II-AT1R-ROS cycle was strongly activated in these 
subjects. The stronger the activation of this cycle, the 
more prominent may be the effects of AT1R blockade. 
Activation of the AGT-Ang II-ROS pathway increases 
the intraglomerular pressure and the ACR. Therefore, 
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Figure 2. Correlation between the reduction rate of the urinary angiotensinogen (UAGT) levels and those of the monocyte chemoattractant protein 
(MCp)-1 A) interleukin (IL)-6 B), and IL-10 (c) levels.Angiotensinogen in nephropathy
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increase  with  UAGT  excretion.  Considering  these 
implications of ROSs and AGT, we expect that the 
efficacy of ARBs increases with the UAGT levels.10 
If this is true, UAGT could serve as a predictive factor 
for the renoprotective effects of ARBs.
The sample size of this study was too small for us to 
arrive at definitive conclusions; further investigation 
with a larger sample size is necessary. Furthermore, 
this study was not a randomized control trial (RCT) 
comparing ARBs with controls. In addition, since we 
did not perform examinations like a renal biopsy, we 
cannot be certain that the DN did in fact improve in 
our patients. Further clinical research is necessary for 
clarifying these issues. This research is a preliminary 
investigation and definitely needs to be followed up 
with a large-scale RCT. A large-scale RCT of this 
type, designated as the ORION-ANGEL (Olmesartan 
Reduces  Inflammation  and  Oxidative  stress  in 
Nephropathy  and  suppresses  ANGiotensinogen 
ELevation)  Study  (UMIN000001618),  is  currently 
underway.
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